Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.38 |
| ▸ | HTR2A | P28223 | 6/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485539 | 0.84 | HTR2C (0.47) | HTR2CHTR2AHTR2B | |
| SCHEMBL6483124 | 0.84 | HTR2C (0.38) | HTR2CHTR2A | |
| SCHEMBL6486605 | 0.82 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL6483629 | 0.81 | ALDH1A1 (0.38) | HTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL6483828 | 0.81 | HTR2C (0.33) | HTR2CHTR2A | |
| SCHEMBL6494697 | 0.79 | HTR2C (0.34) | HTR2CHTR2AHTR2B | |
| SCHEMBL6507041 | 0.78 | HTR2C (0.45) | HTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL6499385 | 0.76 | HTR2C (0.46) | HTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL6852201 | 0.76 | HTR2C (0.58) | HTR2CHTR2AHTR6 | |
| SCHEMBL6482799 | 0.75 | HTR2C (0.36) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
| JP-2002543080-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-6407092-B1 | 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-06-18 | — | — | US | claimed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | claimed |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | disclosed |
| US-6875762-B2 | Tetracyclic azepinoindole compounds | PFIZER (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | PHARMACIA AND UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | disclosed |
| US-6407092-B1 | 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-06-18 | — | — | US | disclosed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | HTR2C 22/4885HTR2A 34/4885HTR2B 86/4885 |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2C 24/4885HTR2A 43/4885HTR2B 184/4885 |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2C 24/4885HTR2A 43/4885HTR2B 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.